News | June 11, 2026
Glenmark launches Winlevi across key European markets
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
The Prayagraj lab is designed to handle both routine and specialised testing
The award places the company in the top 5% globally
Accomplished molecular microbiologist and protein engineer takes charge of CSIR-IMTECH after serving in key scientific and regulatory leadership roles at FSSAI
Digital platform aims to expand access to palliative care through teleconsultations, training, community engagement and global knowledge-sharing
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
Subscribe To Our Newsletter & Stay Updated
